Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
New FDA and EMA Oncology Drug Approvals in Q2 2024 Largely Focused on Biologics and Specific Molecular Targets
In Q2 2024, FDA and EMA approved 26 new/expanded indications and 9 new oncology agents, targeting 19 solid tumors and 5 hematologic malignancies. Highlights include 6 NSCLC treatments, 4 tumor-agnostic approvals, and 3 biologics for follicular lymphoma. Key approvals: alectinib, durvalumab, epcoritamab. Safety updates included hepatotoxicity risks and CAR T-cell therapy warnings.
Verona Wins FDA Approval for COPD Drug, Eyes Q3 Launch
FDA approved Verona Pharma’s Ohtuvayre, a novel COPD treatment with a unique dual-inhibitor mechanism, marking a significant advance in COPD care. Expected to launch in Q3 2024, it improves lung function and reduces exacerbations. Verona secured up to $650M for its rollout, with pricing yet undisclosed.
EHA 2024: Monoclonal antibodies continue to dominate multiple myeloma treatments
At EHA 2024, key studies on MM treatments were presented, including DREAMM-8, LINKER-MM1, and GMMG-HD7. Blenrep showed promising results in RRMM, with a 77% ORR. Linvoseltamab demonstrated efficacy in RRMM, with a 71% ORR. Sarclisa improved treatment responses in newly diagnosed MM, showing higher MRD negativity rates.
Related Clinical Trials:
ASCO24: Sanofi Reports Sarclisa Combo's Fatality
ASCO's annual meeting highlights include BMS's Opdivo/Yervoy combo showing promise in liver cancer, Sanofi's Sarclisa combo reducing multiple myeloma progression, BMS's Breyanzi efficacy in lymphoma, and AstraZeneca's Enhertu improving breast cancer PFS. Other notable updates include GSK's Blenrep in myeloma, AstraZeneca's Imfinzi in lung cancer, and Pfizer/Takeda's Adcetris in Hodgkin lymphoma.
Biotech and Pharma Industry News
John Mulcahy, CEO of SiteOne Therapeutics, notes pain treatment's recent industry resurgence. The company aims to use new funding to achieve 'proof of concept' for its pain medicines.
Intellia Therapeutics Announces First Quarter 2024 Progress and Plans
Intellia Therapeutics advances CRISPR-based therapies, with NTLA-2001 Phase 3 trials for ATTR amyloidosis progressing ahead of schedule. Plans to initiate NTLA-2001 Phase 3 for polyneuropathy by year-end. NTLA-2002 Phase 3 for HAE and NTLA-3001 Phase 1 for AATD to start in 2024. Ended Q1 2024 with $953M in cash.
Odronextamab ASH Presentations Underscore Impressive Outcomes Across B-NHL Subtypes
Odronextamab monotherapy achieved complete responses in all evaluable patients with untreated follicular lymphoma in the OLYMPIA-1 trial. The ELM-1 trial showed durable responses in DLBCL post-CAR-T therapy, and ELM-2 demonstrated high CR rates in relapsed/refractory marginal zone lymphoma. Data presented at ASH 2024 highlight odronextamab's potential across B-NHL subtypes.
Best Biotech Stocks to Buy in 2025
The golden age of biotechnology is marked by scientific advances in disease treatment and prevention, offering investment opportunities. Key companies like Axsome Therapeutics, Exelixis, Intellia Therapeutics, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, and Twist Bioscience are leading with innovative drugs and technologies. The COVID-19 pandemic has further accelerated biotech advancements, especially in treatments and vaccines.
Biotechnology Market Size to Reach USD 5.68 Trillion by 2033
The global biotechnology market, valued at USD 1.54 Trillion in 2023, is projected to reach USD 5.68 Trillion by 2033, growing at a CAGR of 13.95%. Growth is driven by government support, personalized medicine, COVID-19 vaccine development, agricultural biotech applications, and advancements in gene editing and synthetic biology. North America leads the market, while Asia Pacific is expected to grow the fastest.
FDA flexes its new accelerated approval authorities, hoping to signal potential use of new 2022 authority
FDA rejected Regeneron's applications for accelerated approval due to the absence of a confirmatory study, signaling potential use of new 2022 authority, possibly facing criticism for delaying serious disease treatments.
© Copyright 2025. All Rights Reserved by MedPath